China Resources Pharmaceutical Group will kick off its initial public offering in Hong Kong in the next few days, hoping to raise up to $2 billion for…

Piramal added to its run of healthcare acquisitions with a $175 million deal to buy five injectable pain drugs from Johnson & Johnson.

Samsung Bioepis has submitted a biosimilar version of Roche's breast cancer blockbuster Herceptin in the EU, hard on the heels of rivals Biocon and Mylan.

Hanmi Pharma gained one big deal with Roche this week but lost another tie-up with Boehringer--and investors didn't like it one bit.

With forced price cuts for brands such as Gilead Sciences' hep C med Sovaldi already under its belt, the Japanese government is weighing others to help…

Dr. Reddy's will sell three of Amgen's already-approved drugs in India, extending an earlier deal involving three late-stage pipeline candidates.

Chairman Zhou Jie resigns just three months after taking on the role.

Chinese-American diagnostics specialist says it is building a new La Jolla lab to support U.S. product launches.